Selected Breast Cancer Publications from 2015 Authored by DCTB Investigators

Selected breast cancer publications from 2015 authored by DCTB investigators

Frankum J, Moudry P, Brough R, Hodny Z, Ashworth A, Bartek J, Lord CJ. Complementarygeneticscreensidentify the E3 ubiquitinligase CBLC, as a modifier of PARP inhibitor sensitivity.Oncotarget. 2015 May 10;6(13):10746-58.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PH, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015 May 28;521(7553):541-4.

Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm A-V, Ditzel HJ. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Breast Cancer Res Treat. In press, 2015.

Wee ZN, SM Yatim, VK Kohlabauer, M Feng, JY Goh, B Yi, P Leng Lee, S Zhang, PP Wang, WL Tam, Y Cai, HJ Ditzel, DS Hoon, EY Tan, Q Yu. IRAK1 is a therapeutictargetthat drives breast cancer metastasis and resistance to paclitaxel. Nature Communications, 6:8746, 2015.

Kümler I, Stenvang J, Moreira J, Brünner N,Nielsen DL. Drug transporters in breast cancer: response to anthracyclines and taxanes. Expert Rev Anticancer Ther. 2015;15(9):1075-92.

Ignatiadis M, Azim H, Desmedt C, Veys I, Larsimont D,R Salgado, MB Lyng, G Viale, B Leyland-Jones, A Giobbie-Hurder, R Kammler, I Laios, P Dell’Orto, HJ Ditzel, M Regan, M Piccart, S Michiels, C Sotiriou. Genomic grade and centrally-reviewed Ki67 to determine the risk of distant recurrence in the BIG 1-98 phase III trial. JAMA Oncology, in press, 2015.

Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC. A SynergisticInteractionbetween Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.Cell. 2015 Jul 2;162(1):146-59.

Hubackova S, Kucerova A, Michlits G, Kyjacova L, Reinis M, Korolov O, Bartek J, Hodny Z. IFNγinducesoxidative stress, DNA damage and tumor cellsenescence via TGFβ/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.Oncogene. 2015 May 18. doi: 10.1038/onc.2015.162. [Epubahead of print]

Kümler I, Balslev E, Poulsen TS, Nielsen SL, Nygård SB, Rømer MU, Christensen IJ, Høgdall E, Moreira J, Nielsen DL, Brünner N, Stenvang J. Topoisomerase-1 gene copyaberrations arefrequent in patients with breast cancer.Int J Cancer. 2015 Oct 15;137(8):2000-6. doi: 10.1002/ijc.29556. Epub 2015 Apr 27.

Elias D, HJ Ditzel. The potential of Src inhibitors. Aging. 2015 Oct 2. [Epubahead of print]

Lund RR, Leth-Larsen R, Caterino TD, Terp MG, Nissen J, Lænkholm AV, Jensen ON, Ditzel HJ.NADH-cytochrome b5 reductase 3 promotes colonization and metastasis formation and is a prognostic marker of disease-free and overall survival in estrogen receptor-negative breast cancer.Mol Cell Proteomics. 14(11):2988-2999, 2015

Elias D, HJ Ditzel. Fyn is an importantmolecule in cancer pathogenesis and drug resistance. Pharmacol Research, 100:250-254, 2015.

Maheswaran E, Pedersen CB, Ditzel HJ, Gjerstorff MF. Lack of ADAM2, CALR3 and SAGE1 cancer/testis antigen expression in lung and breast cancer. PLoS One. 2015;10(8):e0134967.

Kodahl AR, Pallisgaard N, AM Jylling, Cold S, Knoop AS, Ditzel HJ. Detecting Plasma Tumor DNA in Early-Stage Breast Cancer - Letter. Clin Cancer Res. 21:3569, 2015.

Kümler I, Parner VK, Tuxen MK, Skjoldbye B, Bergenfeldt M, Nelausen KM, Nielsen DL. Clinicaloutcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer.Radiol Med. 2015 Jun;120(6):536-41. doi: 10.1007/s11547-014-0489-6. Epub 2015 Jan 9.

ThomsenKG, MG Terp, RR Lund, R Søkilde, D Elias, M Bak, T Litman, HC Beck, MB Lyng, HJ Ditzel. miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cellextravasation and colonization in vivo and causessignificantsignaling alterations. Oncotarget 6(30):29224-39, 2015.

Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy.Oncotarget 6:15772-15787, 2015.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, …, Viale G, Rae JM, Regan MM. YP19A1 polymorphisms and clinicaloutcomes in postmenopausalwomen with hormone receptor-positive breast cancer in the BIG 1-98 trial.Breast Cancer Res Treat. 151:373-384, 2015.

Ehmsen S, Hansen LT, Bak M, Brasch-Andersen C, Ditzel HJ, Leth-Larsen R. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.Int J Cancer. 137(9): 2093-103, 2015.

ElleIC, KarlsenKK, TerpMG, LarsenN, NielsenR, DerbyshireN, MandrupS, Ditzel HJ, WengelJ. Selection of LNA-containing DNA aptamersagainstrecombinant human CD73. Mol Biosyst. 11(5): 1260-1270, 2015

Hansen SN, Westergaard D, Thomsen MB, Vistesen M, Do KN, Fogh L, Belling KC, Wang J, Yang H, Gupta R, Ditzel HJ, Moreira J, Brünner N, Stenvang J, Schrohl AS. Acquisition of docetaxelresistance in breast cancer cellsrevealsupregulation of ABCB1 expression as a keymediator of resistanceaccompanied by discreteupregulation of otherspecific genes and pathways.TumourBiol. 6:4327-38, 2015.

Fugger K, Mistrik M, Neelsen KJ, Yao Q, Zellweger R, Kousholt AN, Haahr P, Chu WK, Bartek J, Lopes M, Hickson ID, Sørensen CS.FBH1 Catalyzes Regression of Stalled Replication Forks.Cell Rep. 2015 Mar 10. pii: S2211-1247(15)00174-6.

Alsara M, Löffler H, Fechter A, Bartek J, Krämer A.Cep63 recruits cdk1 to the centrosome-letter.Cancer Res. 2015 Feb 15;75(4):777-8. doi: 10.1158/0008-5472.CAN-14-3431.

Kümler I, Balslev E, Stenvang J, Brünner N, Nielsen D. A phase II study of weeklyirinotecan in patients with locallyadvanced or metastatic HER2- negative breast cancer and increasedcopynumbers of the topoisomerase 1 (TOP1) gene: a studyprotocol.BMC Cancer. 2015 Feb 21;15:78.

EliasD, VeverH, LænkholmA-V, Gjerstorff MF, YdeCW, LykkesfeldtAE, DitzelHJ. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene 34:1919-27, 2015